Naprod Life Sciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Naprod Life Sciences Private Limited Pharmaceutical Export Portfolio Dataset — 23 Products, $18.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Naprod Life Sciences Private Limited — Pharmaceutical Exporter Profile (2026) | 23 Products, $18.7M Trade | TransData Nexus

Naprod Life Sciences Private Limited

Indian Pharmaceutical Exporter · Oncology Specialist · $18.7M Total Trade · DGFT Verified

Naprod Life Sciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $18.7M across 23 products in 4 therapeutic categories. Based on 847 verified export shipments from Indian Customs (DGFT) records, Naprod Life Sciences Private Limited is the #1 Indian exporter in 1 product including Vinblastine. Top exports include Carboplatin ($2.6M), Fluorouracil ($1.8M), Oxaliplatin ($1.5M).

Naprod Life Sciences Private Limited — Export Portfolio & Destination Treemap

Naprod Life Sciences Private Limited pharmaceutical export portfolio — 23 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Naprod Life Sciences Private Limited? — Company Overview & Market Position

Naprod Life Sciences Private Limited, established on July 30, 1990, is a private unlisted pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company operates under the Corporate Identification Number (CIN) U24230MH1990PTC057496 and is registered with the Registrar of Companies, Mumbai. Initially known as Neon Antibiotics Private Limited, it rebranded to Naprod Life Sciences Private Limited in 2006.

The authorized capital of Naprod Life Sciences is ₹4.00 crore, with a paid-up capital of ₹3.02 crore. As of the latest available data, the company employs approximately 504 professionals. The registered office is located at 304 Town Centre, Andheri Kurla Road, Andheri (East), Mumbai, Maharashtra, 400059.

What Does Naprod Life Sciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Carboplatin$2.6M 2Fluorouracil$1.8M

Product Portfolio — Top 23 by Export Value

Naprod Life Sciences Private Limited exports 23 pharmaceutical products across 4 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Carboplatin	Oncology	$2.6M	64	3.7%	8
2	Fluorouracil	Oncology	$1.8M	112	13.7%	3
3	Oxaliplatin	Advanced Oncology	$1.5M	51	3.2%	7
4	Methotrexate	Immunosuppressants	$1.2M	45	3.3%	6
5	Gemcitabine	Oncology	$1.1M	45	2.4%	11
6	Paclitaxel	Oncology	$1.1M	70	1.4%	15
7	Mitomycin	Advanced Oncology	$1.1M	29	9.1%	3
8	Doxorubicin	Oncology	$1.1M	85	1.6%	10
9	Capecitabine	Advanced Oncology	$946.4K	27	1.1%	10
10	Epirubicin	Advanced Oncology	$870.1K	23	13.6%	4
11	Vancomycin	Antibiotics	$854.6K	48	0.9%	14
12	Pemetrexed	Advanced Oncology	$812.5K	32	2.8%	8
13	Docetaxel	Oncology	$608.8K	41	1.5%	13
14	Letrozole	Advanced Oncology	$581.6K	12	1.8%	6
15	Cytarabine	Advanced Oncology	$557.0K	52	5.2%	3
16	Cisplatin	Oncology	$507.6K	29	3.9%	7
17	Bleomycin	Advanced Oncology	$485.6K	13	8.7%	2
18	Gefitinib	Advanced Oncology	$327.9K	11	4.8%	4
19	Vincristine	Oncology	$227.7K	15	11.2%	2
20	Irinotecan	Oncology	$165.1K	18	0.4%	12
21	Dacarbazine	Advanced Oncology	$133.7K	16	9.4%	2
22	Vinblastine	Oncology	$128.5K	5	17.1%	1
23	Daunorubicin	Advanced Oncology	$57.6K	4	8.3%	3

Naprod Life Sciences Private Limited exports 23 pharmaceutical products across 4 therapeutic categories with a total export value of $18.7M. The company is the #1 Indian exporter in 1 product: Vinblastine. The top category is Oncology (50.1% of portfolio), followed by Advanced Oncology (39.2%), reflecting a diversified portfolio where the top 5 products account for only 43.9% of total value.

Naprod Life Sciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Naprod Life Sciences operates a state-of-the-art manufacturing plant situated in Tarapur, Thane, Maharashtra. This facility specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, with a strong emphasis on oncology and anesthesia products. The plant adheres to current Good Manufacturing Practices (cGMP) as outlined by the World Health Organization (WHO), ensuring high-quality production standards.

3Key Leadership

The leadership team at Naprod Life Sciences includes:

Mohan Babulal Jain – Director, appointed on March 2, 1994.

Manish Babulal Jain – Director, appointed on September 11, 2018.

Aarya Mohan Jain – Additional Director, appointed on March 13, 2025.

These individuals play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Naprod Life Sciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Naprod Life Sciences has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for its finished pharmaceutical formulations from regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, Therapeutic Goods Administration (TGA) in Australia, and Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. These approvals facilitate the company's market access and distribution in these regions.

2Emerging Markets

Naprod Life Sciences has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products have received prequalification from the World Health Organization (WHO), enabling access to these regions. This prequalification underscores the company's commitment to meeting international quality standards and broadens its market reach.

3Geographic Strategy

The company's geographic strategy demonstrates a balanced approach, with a strong presence in both regulated and emerging markets. This diversification mitigates concentration risk and positions Naprod Life Sciences to leverage growth opportunities across different regions. The strategic direction focuses on expanding market share in oncology and anesthesia segments globally.

Naprod Life Sciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Naprod Life Sciences has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulatory standards. The company has received approvals for its Abbreviated New Drug Applications (ANDAs) and has filed Drug Master Files (DMFs) for its products. The facilities have undergone FDA inspections, which have been completed satisfactorily, reflecting the company's commitment to maintaining high-quality manufacturing practices.

2WHO & EU GMP

The manufacturing facility of Naprod Life Sciences is accredited with Good Manufacturing Practice (GMP) certifications from the World Health Organization (WHO) and the European Union (EU). These certifications affirm the company's adherence to international quality standards in pharmaceutical manufacturing.

3CDSCO & Indian Regulatory

In India, Naprod Life Sciences holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and approvals from state drug controllers. The company has obtained No Objection Certificates (NOCs) for export from the Directorate General of Foreign Trade (DGFT), facilitating its international trade operations.

Naprod Life Sciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the oncology and anesthesia segments, Naprod Life Sciences faces competition from both domestic and international pharmaceutical companies. While specific market share data is not publicly disclosed, the company's focus on high-quality, specialized formulations positions it favorably in niche markets. The company's adherence to international quality standards and its global regulatory approvals enhance its competitive edge.

2Key Differentiators

Naprod Life Sciences distinguishes itself through its specialization in oncology and anesthesia products, leveraging advanced manufacturing technologies such as lyophilization. The company's commitment to innovation, high-quality production, and adherence to international regulatory standards are key competitive advantages.

3Strategic Position

Naprod Life Sciences is strategically positioned as a leading manufacturer of specialized pharmaceutical formulations, focusing on oncology and anesthesia. The company's future outlook includes expanding its product portfolio, enhancing manufacturing capabilities, and increasing market penetration in both regulated and emerging markets. The strategic direction emphasizes innovation, quality, and global market expansion.

Buyer Due Diligence Brief — Evaluating Naprod Life Sciences Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Naprod Life Sciences has a strong track record in pharmaceutical manufacturing, with a focus on oncology and anesthesia products. The company's export volume and consistency are supported by its adherence to international quality standards and regulatory approvals. Reliability indicators include its WHO and EU GMP certifications, FDA approvals, and successful inspections by regulatory authorities.

2Certifications to Verify

Importers should verify the following certifications when considering Naprod Life Sciences as a supplier:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

WHO GMP Certification: Ensure the manufacturing facility holds Good Manufacturing Practice certification from the World Health Organization.

EU GMP Certification: Verify the facility's compliance with Good Manufacturing Practice standards as recognized by the European Union.

Frequently Asked Questions — Naprod Life Sciences Private Limited

How many pharmaceutical products does Naprod Life Sciences Private Limited export from India?

Naprod Life Sciences Private Limited exports 23 pharmaceutical products across 4 therapeutic categories. The top exports are Carboplatin ($2.6M), Fluorouracil ($1.8M), Oxaliplatin ($1.5M), Methotrexate ($1.2M), Gemcitabine ($1.1M). Total export value is $18.7M.

What is Naprod Life Sciences Private Limited's total pharmaceutical export value?

Naprod Life Sciences Private Limited's total pharmaceutical export value is $18.7M, based on 847 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Naprod Life Sciences Private Limited the #1 Indian exporter?

Naprod Life Sciences Private Limited is the #1 Indian exporter in 1 products: Vinblastine (17.1% market share).

What therapeutic categories does Naprod Life Sciences Private Limited cover?

Naprod Life Sciences Private Limited exports across 4 therapeutic categories. The largest are Oncology (50.1%, 10 products), Advanced Oncology (39.2%, 11 products), Immunosuppressants (6.1%, 1 products).

Get Full Naprod Life Sciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.